GSK, Prosensa muscular dystrophy drug misses study goal

LONDON, Sept 20 Fri Sep 20, 2013 7:09am EDT

LONDON, Sept 20 (Reuters) - An experimental drug for Duchenne muscular dystrophy from GlaxoSmithKline and Prosensa failed to meet its goal in a late-stage clinical trial, the companies said on Friday.

The drug, drisapersen, did not show a statistically significant improvement in the distance that patients could walk in six minutes compared to placebo in the Phase III test.